62 related articles for article (PubMed ID: 27311283)
21. [Isolation of apolipoproteins A-I, A-II and E and their estimation by rocket immunoelectrophoresis in blood plasma of dis-alpha-lipoproteinemic patients].
Klimov AN; Usatenko MS; Denisenko AD; Kozhevnikova KA; Oleĩnik IA
Biokhimiia; 1981 Apr; 46(4):590-602. PubMed ID: 6793091
[TBL] [Abstract][Full Text] [Related]
22. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
Moghadasian MH; McManus BM; Nguyen LB; Shefer S; Nadji M; Godin DV; Green TJ; Hill J; Yang Y; Scudamore CH; Frohlich JJ
FASEB J; 2001 Dec; 15(14):2623-30. PubMed ID: 11726538
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein localization and quantitation in the human intestine.
Green PH; Lefkowitch JH; Glickman RM; Riley JW; Quinet E; Blum CB
Gastroenterology; 1982 Dec; 83(6):1223-30. PubMed ID: 6813184
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein(a) phenotypes predict the severity of coronary artery stenosis.
Ducas J; Silversides C; Dembinski TC; Chan MC; Tate R; Dick A; Nixon P; Ren S; Shen GX
Clin Invest Med; 2002 Jun; 25(3):74-82. PubMed ID: 12137255
[TBL] [Abstract][Full Text] [Related]
25. Antiatherogenic effects of dietary plant sterols are associated with inhibition of proinflammatory cytokine production in Apo E-KO mice.
Nashed B; Yeganeh B; HayGlass KT; Moghadasian MH
J Nutr; 2005 Oct; 135(10):2438-44. PubMed ID: 16177209
[TBL] [Abstract][Full Text] [Related]
26. Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis.
Sharma A; Sharma C; Sharma L; Wal P; Mishra P; Sachdeva N; Yadav S; Vargas De-La Cruz C; Arora S; Subramaniyan V; Rawat R; Behl T; Nandave M
Can J Physiol Pharmacol; 2024 May; 102(5):305-317. PubMed ID: 38334084
[TBL] [Abstract][Full Text] [Related]
27. Recombinant apolipoproteins for the treatment of vascular diseases.
Sirtori CR; Calabresi L; Franceschini G
Atherosclerosis; 1999 Jan; 142(1):29-40. PubMed ID: 9920503
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein A-IV of diabetic-foot patients upregulates tumor necrosis factor α expression in microfluidic arterial models.
Ji J; Zhao X; Huang J; Wu X; Xie F; Li L; Wang T; Mi S
Exp Biol Med (Maywood); 2023 Apr; 248(8):691-701. PubMed ID: 36775868
[TBL] [Abstract][Full Text] [Related]
29. Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus-infected macaques: relations between apolipoprotein concentrations and severity of brain injury.
Saito K; Seishima M; Heyes MP; Song H; Fujigaki S; Maeda S; Vickers JH; Noma A
Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):145-9. PubMed ID: 9003413
[TBL] [Abstract][Full Text] [Related]
30. The rat, a useful animal model for pharmacological studies on apolipoprotein E.
Leininger-Muller B; Siest G
Life Sci; 1996; 58(6):455-67. PubMed ID: 8569418
[TBL] [Abstract][Full Text] [Related]
31. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis.
Navab M; Anantharamaiah GM; Fogelman AM
Trends Cardiovasc Med; 2008 Feb; 18(2):61-6. PubMed ID: 18308197
[TBL] [Abstract][Full Text] [Related]
32. Apo D and Apo E levels in Autism spectrum disorders.
Esnafoglu E; Cırrık S
Asian J Psychiatr; 2022 Jul; 73():103177. PubMed ID: 35623271
[No Abstract] [Full Text] [Related]
33. Development and Evaluation of a New Creatine Kinase MB Mass Determination Assay Using a Latex Agglutination Turbidimetric Immunoassay with an Automated Analyzer.
Hoshino T; Hanai K; Tanimoto K; Nakayama T
Clin Lab; 2016; 62(5):877-85. PubMed ID: 27349014
[TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
Marais AD
Pathology; 2019 Feb; 51(2):165-176. PubMed ID: 30598326
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Differentially Expressed Proteins Involved in Autoimmune Cirrhosis and Normal Serum by iTRAQ Proteomics.
Minghui Z; Kunhua H; Yunwen B; Hongmei L; Jing L; Shaowen W; Longqiaozi S; Chaohui D
Proteomics Clin Appl; 2019 May; 13(3):e1700153. PubMed ID: 29999587
[TBL] [Abstract][Full Text] [Related]
36. Effects of blood lipid stability on progression of carotid atherosclerosis.
Ding Y; Li B; Tian F; Zhou S; Chen Y
Pak J Med Sci; 2017; 33(3):599-602. PubMed ID: 28811778
[TBL] [Abstract][Full Text] [Related]
37. [Physiological Function of Apolipoproteins and Atherosclerosis].
Seishima M
Rinsho Byori; 2016 Feb; 64(2):186-92. PubMed ID: 27311283
[TBL] [Abstract][Full Text] [Related]
38. Effect of plasma oncotic pressure on apolipoprotein levels in rats with Heymann nephritis.
Kaysen GA; Jones H; Joles JA; van Tol A
Miner Electrolyte Metab; 1996; 22(1-3):31-8. PubMed ID: 8676821
[TBL] [Abstract][Full Text] [Related]
39. Postnatal blocking of interferon-gamma function prevented atherosclerotic plaque formation in apolipoprotein E-knockout mice.
Koga M; Kai H; Yasukawa H; Kato S; Yamamoto T; Kawai Y; Kusaba K; Seki Y; Kai M; Egashira K; Kataoka Y; Imaizumi T
Hypertens Res; 2007 Mar; 30(3):259-67. PubMed ID: 17510508
[TBL] [Abstract][Full Text] [Related]
40. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
